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ABSTRACT
Treatment of HIV-infected individuals with antire-
troviral agents selects for drug-resistant mutants,
resulting in frequent treatment failures. Although
the major antiretroviral resistance mutations are
routinely characterized by DNA sequencing, treat-
ment failures are still common, probably in part
because undetected rare resistance mutations
facilitate viral escape. Here we combined DNA bar
coding and massively parallel pyrosequencing to
quantify rare drug resistance mutations. Using DNA
bar coding, we were able to analyze seven viral
populations in parallel, overall characterizing
118093 sequence reads of average length 103bp.
Analysis of a control HIV mixture showed that
resistance mutations present as 5% of the popula-
tion could be readily detected without false positive
calls. In three samples of multidrug-resistant
HIV populations from patients, all the drug-resistant
mutations called by conventional analysis were
identified, as well as four additional low abundance
drug resistance mutations, some of which would be
expected to influence the response to antiretroviral
therapy. Methods for sensitive characterization of
HIV resistance alleles have been reported, but only
the pyrosequencing method allows all the positions
at risk for drug resistance mutations to be inter-
rogated deeply for many HIV populations in a single
experiment.
INTRODUCTION
Antiretroviral resistance is a major threat to successful
anti-HIV treatment. This problem is more frequent among
individuals that started therapy in the 1990s, who were
treated sequentially with single antiviral agents (1),
allowing sequential development of resistance to each
treatment. Therapy with combinations of antiretroviral
drugs is more eﬀective, but nevertheless up to 50% of
individuals currently in care in the US harbor HIV-
resistant viruses (2). These resistant strains can also be
transmitted—more than 15% of recently infected indi-
viduals have acquired viruses that are resistant to at least
one of the major antiretroviral classes (3–5). Current
treatment guidelines in the United States recommend
resistance testing before beginning or changing antiretro-
viral therapy.
In the developing world, where much of the burden of
HIV infection is concentrated, combination therapy is
increasingly available. A sharp increase in drug resistance
is expected as patients become more treatment experi-
enced. Unfortunately, resistance genotyping is generally
unavailable in the developing world due to the prohibitive
expense.
Genotypic and phenotypic methods are commonly used
to detect antiviral resistance in clinical specimens.
Genotypic methods use bulk sequencing of the protease
(PR) and reverse transcriptase (RT) coding regions, which
reports the sequence of the predominant circulating HIV
variants. Resistance mutations conferring reduced sensi-
tivity to the three most widely used drug classes (nucleo-
side and non-nucleoside RT inhibitors and PR inhibitors)
are well characterized, allowing probable resistance
patterns to be inferred from sequence information.
Phenotypic methods rely on cloning the RT and
PR-coding regions from patient samples into a standard
HIV plasmid backbone, allowing generation of viral
stocks and functional analysis of viral drug sensitivity in
short-term culture (1).
Several studies have demonstrated that minor drug-
resistant HIV populations that are not detectable in the
standard assays can impair the response to therapy (6,7).
This problem is particularly apparent in studies of
pregnant women that received single doses of nevirapine,
a non-nucleoside reverse transcriptase inhibitor (NNRTI),
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HIV. In these patients, the presence of minor populations
with resistance to nevirapine—which were often undetect-
able by conventional sequencing—compromised the
response to subsequent NNRTI therapy (8,9).
A variety of technologies have been devised to allow
characterization of minor HIV drug-resistant populations
(7,10,11). In one method, microarrays were designed to
interrogate positions of drug resistance mutations (12).
This technique allows analysis of many genomic posi-
tions in a single experiment, but the method has not
been widely used, in part due to the high cost of each test.
Another method involves allele-speciﬁc RT-PCR,
which allows sensitive detection of single drug resistance
mutations (10). A third approach takes advantage of the
massively parallel polony sequencing method (11), and a
fourth uses an early version of pyrosequencing to query
single nucleotide positions for possible mutations (13).
However, except for the microarray method, all of the
above methods queried individual base pairs at a time
(10). Given that there are over 60 amino acid positions just
in PR and RT that can aﬀect resistance to the three widely
used drug classes, these methods are time consuming and
diﬃcult to use for comprehensive analysis. An ideal
method for investigating drug resistance mutations
would yield many complete sequences of HIV genomic
regions at risk for mutations for each viral population,
and allow analysis of many samples of HIV populations in
a single experiment.
We have adapted pyrosequencing (14), combined with a
DNA bar coding system (15,16), to characterize rare drug-
resistant HIV variants in many samples in parallel. In a
single experiment, we determined 118093 sequences from
 100bp segments of the PR and RT-coding regions for
seven samples of viral populations (Table 1). These data
identiﬁed a variety of minor drug resistance alleles in
patient samples of potential clinical signiﬁcance, and
demonstrate the feasibility of using pyrosequencing for
eﬃcient HIV genotyping. Multiplex analysis of many bar
coded samples in a single sequencing experiment oﬀers the
potential to drive down the cost of each genotype
determination.
MATERIALS AND METHODS
Nucleic acidpurification
DNA primers for PCR ampliﬁcation were obtained from
Invitrogen (Carlsbad, CA, USA). The HIV LAI plasmid
(pLAI) was obtained from Dr Michael Emerman
(Fred Hutchinson Cancer Research Center). HIV LAI
particles were made by transfection of the pLAI and
pVSV-G into 293T cells using standard methods.
Supernatants were collected 3 days after transfection,
concentrated by centrifugation, then treated with DNAse
I to remove possible DNA carried over from the initial
transfection. HIV NL4-3 particles were made similarly but
without adding the pVSV-G plasmid. The following viral
stocks were obtained from the AIDS Reference Reagent
Repository: HIV NL4-3 (L10R/M46I/L63P/V82T/I84V;
Catalog #2840); HIV subtype A (Catalog #7683); HIV
subtype B (Catalog #7686); HIV subtype C (Catalog
#7694); HIV subtype D (Catalog #7699); HIV subtype E
(Catalog #7701).
HIV RNA from patient plasma samples was puriﬁed in
the high-throughput facility at the Children’s Hospital
of Philadelphia using the Magna-Pure System (Roche) by
Dr R. Hodinka. Viral loads were patient 1: 736000c/ml;
patient 2: 105000c/ml; patient 3: 105000c/ml. Other HIV
RNA samples were puriﬁed using the Illustra RNAspin
mini RNA Isolation Kit (GE Health Care, Piscataway,
NJ, USA).
PCR amplification
For the primer design, representative sequences (341 total)
from subtypes A–D and G were downloaded from
the Los Alamos HIV Database and Compendia
(http://www.hiv.lanl.gov). Subtype consensus sequences
were formed by aligning sequences within each subtype,
then ‘Pan-HIV’ primers were designed to anneal to
sequences conserved among subtypes (Supplementary
Table 1).
All samples were ampliﬁed using the OneStep RT-PCR
Kit (QIAGEN, Valencia, CA, USA) following the
manufacturer’s instructions. RNasin RNAse inhibitor
(Promega, Madison, WI, USA) was added to the reaction
to a ﬁnal concentration of 0.5units/ml. Five thousand
copies of nucleic acid templates per reaction were used for
the LAI DNA, LAI RNA and NL4-3 RNA mixture.
For the patient samples, 10ml of eluted material from the
nucleic acid extraction was used as template. The RT-PCR
reaction was carried out using a GeneAmp PCR System
9700 (Applied Biosystems, Foster City, CA, USA). The
program used was: 1 cycle of 458C for 45min followed by
15min at 958C; 14 touch-down cycles with annealing
temperature from 558Ct o4 8 8C for 30s followed by 26
cycles with annealing temperature of 488C for 30s. A ﬁnal
extension of 10min at 728C was used. The denaturing and
extension temperatures were 948C and 728C, respectively,
Table 1. Viral populations characterized in this study
Sample Ampliﬁcation template Description Bar code Number of sequence reads
1 Viral RNA HIV LAI RNA from particles d(ACTG) 17434
2 Plasmid DNA HIV LAI cloned DNA d(AGTC) 13856
3 Viral RNA HIV NL4-3 mixed with drug resistant NL4-3 d(CTGA) 7398
4 Viral RNA Mixture of HIV particles from subtypes A-E d(CGTA) 28751
5 Viral RNA HIV quasispecies from patient 1 d(GCTA) 19079
6 Viral RNA HIV quasispecies from patient 3 d(TAGC) 10730
7 Viral RNA HIV quasispecies from patient 2 d(TGAC) 20845
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tion step using Taq polymerase is 2–3 misincorporation
events in 100000, and for the RT step51 substitution in
30000 (estimates provided by Qiagen, Valencia, CA,
USA).
PCR products were separated by electrophoresis on
TAE agarose gels, slices containing the bands of interest
were excised, DNA was extracted using the Qiagen Gel
Extraction Kit (Valencia, CA, USA), then samples were
pooled (75ng per amplicon). For sequencing, the con-
centrations of DNA were adjusted to  5–15ng/ml.
Conventional analysis ofHIV genotypesin patients
Patient 1 was treated with tenofovir, FTC, atazanvir and
ritonavir; patient 2 is deceased and treatment history is
unknown, and patient 3 was treated with retrovir
(zidovudine), epivir (lamivudine; 3TC) and viracept
(nelﬁnavir). The conventional clinical analysis of HIV
genotypes for the three patients studied was carried out as
follows. Plasma viral RNA was extracted, ampliﬁed by
RT-PCR (Roche Amplicor v 1.0; Roche Diagnostic
Systems, Inc., Branchburg, NJ, USA), and sequenced
using the Viroseq HIV Genotyping System v 2.0 (Applied
Biosystems, Foster City, CA, USA). The sequences were
analyzed for the resistance mutations using the HIV Drug
Resistance Database at Stanford University (http://
hivdb.stanford.edu/) (17), then calls were edited to
match the slightly diﬀerent catalog from the
International AIDS Society Drug Resistance Mutations
in HIV (Fall 2006) (2).
Pyrosequencing
Pyrosequencing was carried out using the 454 Life
Sciences Technology at the University of Florida. The
pyrosequencing method, as implemented by 454 Life
Sciences, involves the following steps. Genomic DNA
samples of interest are ampliﬁed using primers that
include 50 extensions providing binding sites for the
454A and B primers. DNA fragments are then mixed
with beads that have bound on their surfaces oligonucleo-
tides complementary to the primers. This step is carried
out in dilute solution so that on average a single DNA
strand binds to each bead. A dilute mixture of beads is
then added to an oil–water emulsion, arranged so that on
average each aqueous droplet contains a single bead
with a single bound strand. PCR ampliﬁcation is then
carried out in the emulsion. Each DNA strand becomes
ampliﬁed and then binds by sequence complementarity
to the bead, thereby creating beads that are each
conjugated to DNA strands of a single homogenous
sequence. Beads with bound DNA are then distributed on
a picotiter plate at a density of  150000 beads per plate.
A primer is then bound to each DNA, and a polymerase
used to extend a DNA chain. The four nucleotide
triphosphates are sequentially ﬂowed over the plate.
An enzyme system is present in the buﬀer, which directs
incorporation of pyrophosphate liberated by nucleotide
addition into ATP, which then activates puriﬁed
luciferase enzyme in the buﬀer to produce light. A CCD
camera records each ﬂash from each well on the plate.
Sequential application of the four nucleotides allows
DNA sequences of  100bp to be built up  150000at a
time (14).
The initial sequence reaction, carried out on a single
plate, yielded 135528 sequence reads, of which 118093
ultimately passed quality control. For the sequences to
pass, we required that each have a perfect match to the bar
code and primer region, and no more than one N in the
determined sequence. A total of 5.1% of the initial
sequence reads had bar codes that were not included in
the original experiment. The pyrosequencing method is
error-prone at homopolymers, and of the incorrect bar
codes, 54% created homopolymeric sequences within the
bar codes and were excluded on that basis. To suppress
bar code ‘crossover’, the diﬀerent viral samples were
separated into separate quadrants of the sequencing plate
as follows (numbers from Table 1): samples 1 and 2,
quadrant 1; samples 3 and 5, quadrant 2; samples 6 and 7,
quadrant 3; sample 4, quadrant 4. Inspection of drug
resistance calls for samples within the same quadrant
showed no obvious bar code crossover.
For scoring drug resistance mutations, we used the
Sierra Webservice at the HIV Drug Resistance Database
at Stanford University (http://hivdb.stanford.edu/).
To query the Drug Resistance Database, the pyrosequence
reads were embedded in ‘dummy’ HIV ﬂanking sequences,
and the resistance alleles identiﬁed over the sequenced
region. To pass quality control at this step, we required
that the full sequence be recognized as HIV by the HIV
Drug Resistance database, and that all pyrosequence
reads cover at least 60% of the genomic window
interrogated. Resistance mutations called by the
Stanford Database were ﬁltered to match the
International AIDS Society deﬁnitions.
Statistical analysis
Inspection of the raw counts of drug resistance calls in
controls (Supplementary Table 2) showed that diﬀerent
positions showed diﬀering error rates. For this reason, a
statistical model was used that took into account the error
rate measured at each position. The proportion of drug-
resistant mutant calls in the combined HIV LAI DNA and
HIV LAI RNA data sets were taken as the background
error for each position. We took advantage of the Fisher’s
exact test to investigate whether drug resistance mutations
were signiﬁcantly enriched in the patient samples com-
pared to controls. To control for multiple comparisons,
a Bonferroni correction was applied. The P-values were
multiplied by the number of comparisons within each
individual (62 comparisons corresponding to 62 codons
queried for drug resistance). Drug resistance calls with
corrected P-values 50.05 were judged to be signiﬁcantly
enriched. Statistical analysis was carried out in the R
environment (http://www.r-project.org/).
RESULTS
DNA bar coding andpyrosequencing
Primers were designed for amplifying the regions of
HIV pol that are known from previous work to be sites
of substitutions that result in resistance to PR and
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ampliﬁcation of HIV sequences from any of the viral
subtypes, we designed ‘Pan-HIV’ primers that would
amplify subtypes A, B, C, D and 01_AE, the major
subtypes circulating world-wide.
Typical read lengths for the pyrosequencing method at
the time of this experiment were  100bp. For the
sequencing procedure, it is desirable to use fragments
that are somewhat longer than this, to allow electro-
phoretic separation of the PCR products away from short
contaminating sequences such as primer dimers. For this
reason, we designed 11 overlapping amplicons, as shown
in Figure 1, to allow analysis of all known positions of PR
and RT drug resistance mutations [cataloged by the
International AIDS Society (Fall 2006 Revision) (18)]
while allowing puriﬁcation of fragments in the 200–400bp
size range.
Viral populations studied
A key consideration in analyzing our results was
distinguishing authentic drug-resistant mutations from
erroneous calls. After isolation of HIV RNA from
particles, reverse transcription followed by PCR
(RT-PCR) has the potential to introduce mutations. The
pyrosequencing procedure, as implemented at 454 Life
Sciences (14), also requires a PCR ampliﬁcation step, and
the pyrosequencing method is more error prone than the
Sanger method.
Several controls were therefore included in the experi-
ment to allow estimation of the background error rate
(Table 1). Plasmid DNA from the HIV isolate LAI was
used as template for PCR ampliﬁcation by the 11 pan-
HIV primers and the products analyzed. Because the HIV
LAI DNA sequence is known, this serves as a control for
error in the RT-PCR and pyrosequencing steps. RNA
from HIV LAI viral particles was included as another
control. This provided a second measure of error and also
allowed us to assess the misincorporation rate due to
transcription and reverse transcription of the HIV RNA,
which proved to be undetectable using the methods
described later.
As a test of the detection sensitivity, we studied RNA
from particles of another strain, HIV NL4-3, which were
‘spiked’ with one-twentieth the amount of a drug-resistant
HIV NL4-3 derivative containing ﬁve substitutions in the
PR-coding region (encoding L10R/M46I/L63P/V82T/
I84V). Viral stocks were normalized by measuring the
amount of the p24 capsid protein in each stock by ELISA.
A fourth sample contained a pool of ﬁve HIV subtypes
(A, B, C, D and 01AE) (19), and was included to illustrate
the ability of the pan-HIV primers to amplify sequences
from all ﬁve, and the downstream bioinformatic methods
to distinguish sequence data from each.
We also studied three samples of plasma from patients
with drug-resistant HIV. For each of the three, we
obtained standard diagnostic sequence data generated
previously using the Viroseq HIV Genotyping System v
2.0 (Applied Biosystems, Foster City, CA, USA) and used
in managing each patients’ treatment. Analysis of these
samples allowed us to compare the sensitivity of the
pyrosequencing method to a standard method.
The DNA barcoding strategy
Since one of our goals was developing methods for testing
many samples in single sequencing experiments, we
developed a DNA bar coding strategy to allow sample
multiplexing (Figure 2). Each primer consisted of the
454A and B sequences at the 50 ends, required for the
emulsion PCR, and the HIV-complementary regions at
the 30 end. To distinguish diﬀerent amplicons in a pool,
we added a 4bp DNA bar code sequence between the
454A or B sequence and the HIV-complementary region.
5′-  GCCTCCCTCGCGCCATCAG- atcg -ATCACTTCTTTGGCARCGACC  -3′
454 primer
A or B
Bar
code
HIV-1 primer
HIV DNA
A
HIV primer
barcode
Sample
primer
sequence
B
HIV primer
barcode
Figure 2. The DNA bar coding system. Primers are shown diagrammatically, illustrating the placement of the DNA bar code between the 454
primers (A and B) and the HIV-complementary sequences. An example of a primer sequence is shown at the bottom. DNA 50 ends in the primers are
shown as the black balls.
Amplicons
GAG
VPR VPU
VIF ENV
NEF
TAT
REV
Pol
PR RT
Figure 1. Amplicons querying positions of HIV drug resistance
mutations in the PR and RT-coding regions. The HIV genetic map is
shown at the top. Below is shown an expanded version of the segment
of pol encoding PR and part of RT. At the bottom is shown the
location of the amplicons used to interrogate positions of potential
drug resistance mutations.
e91 Nucleic Acids Research, 2007, Vol. 35, No. 13 PAGE4 OF 8Because the 454 sequencing method has an increased
error rate at positions of adjacent nucleotides of the same
type (homopolymers), we avoided using bar codes
containing adjacent identical nucleotides.
Sample amplification and initial sequence analysis
PCR ampliﬁcation was carried out on the seven HIV
nucleic acid templates listed in Table 1 using the pan-HIV
primers. All ampliﬁcation reactions yielded DNA chains
of the expected length when analyzed by agarose gel
electrophoresis and ethidium bromide staining. Figure 3
shows a sample ampliﬁcation of subtype C viral RNA.
The PCR amplicons were then pooled and subjected to
pyrosequencing using the method implemented by 454
Life Sciences (14). Samples were attached to beads and
ampliﬁed using emulsion PCR, the beads with bound
DNA were applied to a picoliter plate, and sequences on
beads were determined using the pyrosequencing method.
A total of 135528 sequence reads were returned, of
average length 103bp. After quality control, 118093
sequences were available for analysis, corresponding to
 12 million base pairs of DNA sequence. Of the seven bar
codes used, the number of sequences returned per bar code
after quality control ranged from 28751 (pooled subtypes)
to 7398 (NL4-3 with doped drug resistance allele). More
of the PCR products from the subtype pool was used for
sequencing because we expected a relatively higher level
of diversity from this sample due to the diversity of the
templates. Overall, 121 ampliﬁcation products were
pooled and analyzed, and sequences from all were
recovered in good yield.
We next sought to identify mutations within the HIV
sequences expected to confer drug resistance. Sequences
passing quality control were analyzed at the HIV Drug
Resistance Database at Stanford University (http://
hivdb.stanford.edu/) (17), and the results tabulated. For
our initial analysis, we restricted our attention to the best
documented drug resistance mutations as summarized by
the International AIDS Society Drug Resistance
Mutations in HIV (Fall 2006 Revision) (2). Overall,
62 positions of drug resistance were queried, and the
frequency of drug resistance calls at each codon tabulated
(raw data in Supplementary Table 2).
The pool of HIV subtypes (Table 1, sample 4) was
separated into subtype-speciﬁc groups by aligning the
sequences against subtype-speciﬁc consensus sequences.
Sequences were recovered for all ﬁve subtypes in good
yield. Supplementary Table 3 catalogs the sequences
identiﬁed and the drug resistance mutations detected in
each subtype, and Supplementary Table 4 presents the
rate of polymorphism at sites not involved in drug
resistance.
Statistical analysis
A statistical procedure was devised to allow detection
of signiﬁcant enrichment of drug resistance mutations
above the error rate. Inspection of the control data
(HIV LAI DNA and RNA templates) revealed that, of the
124 codons queried (62 codons in each of the two
controls), 57/124 codons showed zero calls for drug
resistance (Supplementary Table 2). All 62 control
codons showed 51% resistance calls. However, 4/124
positions showed erroneous calls for drug resistance
between 0.5% and 1% of sequences. For this reason, a
statistical procedure was devised to assess the possible
presence of drug resistance mutations in the experimental
samples in light of the position-speciﬁc error rate.
The proportion of drug resistance calls at each position
in the controls (Table 1, samples 1 and 2) was assessed and
taken as the position-speciﬁc background. The frequency
of resistance calls in each sample was then tested against
the position-speciﬁc background using Fisher’s exact test.
Inspection of the initial collection of P-values showed that
there were more positions of signiﬁcant enrichment than
expected in the controls (Table 1, samples 1–3), which was
not surprising because the large number of comparisons
carried out (62 for each patient) increased the likelihood of
obtaining signiﬁcant enrichment by chance. To control for
the inﬂation of error due to multiple comparisons, we
applied a Bonferroni correction, in which the P-value
from Fisher’s exact test was multiplied by the number
of comparisons in each patient (62). Thirty-six positions
achieved signiﬁcance after correction (P50.05), and are
shown as black tiles in Figure 4.
Proper performance of this procedure could be veriﬁed
by analyzing the results for the HIV NL4-3 sample spiked
with 5% virions encoding the L10R/M46I/L63P/V82T/
I84V resistance substitutions. All ﬁve doped drug resis-
tance alleles were found to be signiﬁcantly enriched
after the correction for multiple comparisons, and no
additional mutations were called erroneously (Figure 4).
The measured frequencies of the drug resistance alleles,
initially added at 5%, were L10: 4.6%, M46: 1.3%, L63:
4.8%, V82: 2.9%, I84: 3.1%. We conclude that the
pyrosequencing method together with the above statistical
procedure is sensitive and accurate enough to selectively
detect drug resistance substitutions present as 5% of the
viral population.
Drug resistance alleles detectedin patientsamples
Drug resistance mutations were identiﬁed using pyrose-
quencing in the three patient samples (Table 1, samples
5–7), and the calls compared to those called by the Viroseq
PRout
PR1
PR2
PR3
M
RT1
RT2
RT3
RT4
RT5
RTout
500bp
Marker
Figure 3. Ampliﬁcation of HIV subtype C using the pan-HIV primer
set. The ﬁgure shows products of RT-PCR reactions analyzed by
agarose gel electrophoresis and ethidium bromide staining. The
amplicons extend from the 50 side of the PR-coding region (left) to
an internal region of the RT-coding region (right), thereby covering all
the known positions of drug resistance mutations in the PR and RT-
coding regions (primer sequences are in Supplementary Table 1). The
marker ladder has ‘steps’ of 100bp. The position of the 500bp
fragment is marked.
PAGE 5 OF 8 Nucleic Acids Research, 2007, Vol. 35, No. 13 e91HIV Genotyping System (analyzed using the HIV Drug
Resistance Database at Stanford University). The pyro-
sequencing study identiﬁed all 15 of the drug-resistant
mutations that were called using the Viroseq genotyping
pipeline (Figure 4, black bars without asterisks). The
median proportion of mutations called by the Viroseq
method was 88% drug resistance calls as measured in the
pyrophosphate sequencing data (range: 28–99%). Four
additional lower abundance drug resistance mutations
were called in the pyrosequencing data that were not
called by the Viroseq pipeline (Figure 4, black bars with
white asterisks), one for patient 1, one for patient 2 and
two for patient 3 (Figure 4, black bars with asterisks).
The frequency of resistance mutations called by pyrose-
quencing only ranged from 11.6 to 0.65% of the total.
A few positions were represented by many sequences, and
appear to be just below the level of detection of the
conventional genotyping assay. For example, the RT drug
resistance substitution K70R was represented by 40 calls
out of 305, and the RT mutation M184V was represented
by 46 calls out of 726 (both from patient 3). At the other
extreme, signiﬁcant detection could be achieved by as few
as nine drug resistance calls for codons in cases where the
background was low—for the M46 position in patient 1,
drug resistance for 9 out of 1377 calls achieved signiﬁcance
in the presence of a background of 1 out of 2395 calls
(P=0.0014, Fisher’s exact test, two-sided comparison).
The potential clinical signiﬁcance of the minor drug-
resistant alleles is discussed later.
Eight resistance mutations were also identiﬁed in the
collection of sequences from diﬀerent HIV subtypes
(Table 1, sample 4, data summarized in Supplementary
Table 3). The HIV samples studied were isolated from
patients worldwide in 1991 (19). The subtype B sample
was isolated in the United States, subtypes A, C and D in
Uganda, and subtype 01_AE in Thailand. None of the
patients were on antiretroviral therapy at the time of
collection. Eight drug resistance mutations were identiﬁed
* *
* *
*
*
*
L10
I13
G16
K20
L24
D30
V32
L33
E34
E35
M36
K43
M46
I50
F53
I54
Q58
I47
G48
D60
I62
L63
I64
H69
A71
G73
T74
L76
V77
V82
N83
I84
I85
N88
L89
L90
I93
M41
A62
K65
D67
T69i
K70
L74
V75
F77
L100
K103
V106
V108
Y115
F116
Q151
Y181
M184
Y188
G190
L210
T215
K219
P225
P236
*
*
*
PR
DRM Codon 
HIV Samples
HIV LAI DNA 
HIV LAI RNA
HIV NL4-3 (spiked)
HIV Subtypes A-E
Patient 1
Patient 2
Patient 3
PR (cont.)
DRM Codon
HIV Samples
HIV LAI DNA
HIV LAI RNA
HIV NL4-3 (spiked)
HIV Subtypes A-E
Patient 1
Patient 2
Patient 3
DRM Codon
HIV Samples
HIV LAI DNA
HIV LAI RNA
HIV NL4-3 (spiked)
HIV Subtypes A-E
Patient 1
Patient 2
Patient 3
DRM Codon
HIV Samples
HIV LAI DNA
HIV LAI RNA
HIV NL4-3 (spiked)
HIV Subtypes A-E
Patient 1
Patient 2
Patient 3
RT
RT (cont.)
Figure 4. Summary of the drug resistance alleles detected. Results are shown for PR (top two grids) and RT (bottom two grids). The seven HIV
samples studied are labeled to the left of each grid. The amino acid positions of drug-resistant mutations are marked at the top of the grid, labeled
DRM for drug resistance mutation. Black tiles in the grid indicate positions that were signiﬁcantly enriched for drug resistance mutations in the
pyrosequencing data after correction for multiple comparisons. Raw counts are available in Supplementary Table 2. Black tiles with asterisks indicate
positions that were enriched in drug resistance mutations in the pyrosequencing data that were not identiﬁed by a conventional genotyping method
(Viroseq HIV Genotyping System v 2.0). The ‘i’ at RT position 69 denotes the insertions at this position that are known to confer drug resistance.
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the resistance mutations were present as substantial
fractions of the populations, such as the M36I substitution
in subtype D, which comprises more than 78%. Others
were less common, comprising  20% of the population.
It is uncertain how many of these mutations, which appear
to be pre-existing polymorphisms, would inﬂuence sensi-
tivity to protease inhibitors (20,21). Taken together, these
ﬁndings demonstrate the ability of the pyrosequencing
method to identify minor drug resistance mutations in
individuals infected with diverse HIV subtypes.
DISCUSSION
Here we describe the use of DNA bar coding and
pyrosequencing in detecting minor drug resistance muta-
tions in HIV populations. We used pyrosequencing to
generate 118093 sequence reads from the pol region of
seven samples of viral populations or controls. The seven
samples were analyzed in a single sequencing experiment,
made possible by use of DNA bar coding to distinguish
the diﬀerent samples. As controls we analyzed a DNA
plasmid encoding HIV LAI and HIV LAI RNA from viral
particles, allowing an empirical estimation of error at each
codon at risk for mutation to drug resistance. To test
the assay sensitivity, we analyzed a mixture containing
HIV NL4-3 wild-type virions mixed with 5% of mutant
virions containing ﬁve drug resistance mutations. All ﬁve
mutations were called as present in the mixture without
false positives, demonstrating the accuracy of the method.
Analysis of viral populations from three patients harbor-
ing drug-resistant HIV revealed all the mutations called by
the conventional genotyping method (Viroseq), plus four
additional less abundant drug resistance mutations
comprising from 11.6% to 0.65% of the population.
Previously several methods have been reported for
sensitive detection of rare drug-resistant mutations, some
with impressive sensitivity (10,11). However, only the
combination of DNA bar coding and pyrosequencing
oﬀers the opportunity to determine the full sequence of
genomic regions with drug-resistant mutations from many
samples in a single sequencing experiment. Using this
method, sequence polymorphisms that were not speciﬁ-
cally targeted for analysis can be identiﬁed and analyzed
for possible correlations with drug resistance, which is not
possible with most of the alternative methods. Here we
analyzed seven viral populations in a single picoliter
sequencing plate, but there is no reason that the number
could not be much larger. In another study, we have
successfully sequenced 42 diﬀerent DNA bar codes in a
single plate (unpublished data), indicating the potential.
Several of the low abundance drug resistance mutations
detected here are of potential clinical signiﬁcance, since
they may confer reduced sensitivity to drugs that
otherwise might seem attractive for therapy. For example,
patient 3 was found to harbor low level resistance alleles in
RT at K70 and M184, which would be likely to impair
therapy with several of the NRTIs, though not with all
NRTIs. Patient 3 had been treated with NRTIs known to
elicit these mutations, probably explaining their presence.
Because alternative NRTIs are available for which all of
the patient 3 viruses would remain sensitive, knowledge of
the minor alleles could have improved the ability to
choose eﬀective therapy in this case. Looking forward, it
will be important to test more fully the importance of
minor HIV drug-resistant populations on antiretroviral
responses and the impact of such information on
treatment outcomes.
Lastly, the methods described here may be useful in
implementing drug resistance genotyping in resource-
limited settings. Using the DNA bar coding strategy, it
should be possible to multiplex large numbers of patient
samples in single sequencing runs, thereby driving down
costs. Though many logistical obstacles would need to be
overcome, the combination of DNA bar coding and
pyrosequencing oﬀers a prototype technology for aﬀord-
able HIV genotyping.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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